Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
Phase 1
Completed
- Conditions
- Psoriasis Vulgaris
- Registration Number
- NCT00306878
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this clinical research study is to determine the safety, pharmacokinetics, immunogenicity in humans, the recovery time required from the biologic effects and the optimal biologic dose range of BMS188667 (CTLA4Ig)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
- Men or women who received adequate counseling and were judged reliabel in their use of contraceptive measures.
- Diagnosis and documentation of stable psoriasis vulgaris of at least 6 months duration.
- Psoriasis vulgaris total body surface area involvement between 10% and 49% (Overall Disease Severity Score [ODSS]of 4-7 inclusive).
- Failure of toxicity or inefficacy of at least one standard antipsoriatic therapy including topical treatment, etretinate, phototherapy, or methotrexate.
Exclusion Criteria
- Treatment with: a) Retinoids within 2 years, b) cyclosporin A, systemic corticosteroids, methotrexate, or an investigational agent within 16 weeks, c) any phototherapy or photochemotherapy within 4 weeks d) any topical psoriasis treatment other than emollients within 2 weeks prior to enrollment.
- No clinical response to a prior adequate therapeutic trial of cyclosporin A
- Prolonged exposure to the sun within 4 weeks prior to the first dose.
- Guttate, erythrodermic, or pustular psoriasis.
- Spontaneously improving or rapidly deteriorating psoriasis vulgaris.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Change relative to pretreatment of the Overall Disease Severity Score (ODSS) for psoriasis vulgaris as assess by a blinded observer. Phage-Neutralizing anitbody titer at Day 43
- Secondary Outcome Measures
Name Time Method Physician's globas Assessment at Day 36 Mean percentage of anti-bacteriophage FX174 antibody of IgG isotype in sera collected at Day 43 Phage-neutralizing antibody titer at Day 16 and Day 29
Trial Locations
- Locations (1)
Local Institution
🇺🇸Pittsburgh, Pennsylvania, United States